Glaxo Agrees to Buy Stiefel for $2.9 Billion in Cash - Bloomberg
Glaxo Agrees to Buy Stiefel for $2.9 Billion in Cash Bloomberg “It's expanding to other health-care areas to diversify risks, away from being purely pharmaceuticals.” Stiefel, based in Coral Gables, Florida, received unsolicited buyout offers from Johnson & Johnson, Novartis AG and Glaxo, a person familiar with ... |

